Prab: CSV import

2025-02-13T03:49:56Z

CSV import

← Older revision		Revision as of 03:49, 13 February 2025
Line 1:		Line 1:
	~~'''~~Incyte Corporation''' is an American [[biopharmaceutical]] company based in [[Wilmington, Delaware]]. Founded in 1991, Incyte has grown into a leading entity focused on the discovery, development, and commercialization of proprietary therapeutics. The company's efforts are primarily directed towards oncology, including both hematologic and solid tumor malignancies, as well as autoimmune diseases.		== Incyte Corporation ==

	~~==History==~~		[[File:Incyte_logo.svg\|thumb\|right\|Incyte Corporation logo]]
	~~Incyte was established in Palo Alto, California, but later moved its headquarters to Wilmington, Delaware~~. ~~Initially, the company focused on genomic and bioinformatics research, leveraging the burgeoning field of genomics to identify novel drug targets. Over the years,~~ Incyte ~~transitioned from genomics research to drug development, focusing on small molecule drugs and monoclonal antibodies for the treatment of cancer and autoimmune diseases.~~

	~~==Products and Pipeline==~~		'''Incyte Corporation''' is a multinational biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in [[Wilmington, Delaware]], United States.
	Incyte'~~s portfolio includes~~ a ~~range of approved products~~ and ~~investigational compounds in various stages~~ of ~~clinical development~~. ~~One of the~~ company~~'s most notable products~~ is ~~'''Jakafi''' (ruxolitinib), a first-~~in~~-class JAK1/JAK2 inhibitor approved by the~~ [[~~U.S. Food and Drug Administration~~]] ~~(FDA) for the treatment of myelofibrosis~~, ~~polycythemia vera, and graft-versus-host disease. Other products in Incyte's portfolio target different mechanisms of action and pathways involved in disease progression~~.

	~~The~~ company~~'s research and development pipeline is robust~~, with ~~multiple compounds being investigated for the treatment of various cancers~~ and ~~autoimmune conditions~~. ~~Incyte's commitment to innovation is reflected~~ in ~~its ongoing clinical trials and research collaborations aimed at discovering new therapeutic options for patients~~.		== History ==
			Incyte was founded in 1991 as a genomics company. Over the years, it has evolved into a biopharmaceutical company with a focus on oncology and inflammation. The company has developed several drugs that have been approved for use in various countries.

	==~~Collaborations~~==		== Products ==
	~~Incyte has established several strategic collaborations with other pharmaceutical and biotechnology companies. These partnerships leverage~~ Incyte's ~~discovery and development capabilities and provide access to additional resources~~ and ~~expertise~~. ~~Through these collaborations, Incyte aims to accelerate~~ the development of ~~its pipeline~~ and ~~bring new therapies to market more efficiently~~.		Incyte's most notable product is [[ruxolitinib]], marketed under the brand name Jakafi in the United States. Ruxolitinib is a [[Janus kinase inhibitor]] used in the treatment of myelofibrosis and polycythemia vera. The company is also involved in the development of other drugs targeting various types of cancer and inflammatory diseases.

	==~~Corporate Responsibility~~==		== Research and Development ==
	Incyte ~~is committed~~ to ~~ethical business practices and corporate responsibility~~. The company~~'s initiatives focus on patient access to medications, environmental sustainability, and community engagement~~. Incyte~~'s patient assistance programs are designed to support patients who may not have access to their medications due~~ to ~~financial constraints~~.		Incyte invests heavily in [[research and development]] to discover new therapies. The company has a robust pipeline of investigational drugs in various stages of clinical trials. Incyte collaborates with other pharmaceutical companies and research institutions to advance its research efforts.

	==~~Challenges and Controversies~~==		== Corporate Structure ==
	~~Like many companies in the pharmaceutical industry,~~ Incyte ~~faces challenges related to drug pricing, regulatory hurdles,~~ and ~~competition~~. The company~~'s success depends~~ on ~~its ability to navigate these challenges while continuing to innovate and develop new therapies~~.		Incyte operates globally with offices and research facilities in multiple countries. The company is publicly traded on the [[NASDAQ]] stock exchange under the ticker symbol INCY.

	==~~Future Outlook~~==		== Community Involvement ==
	Incyte~~'s future prospects are closely tied~~ to ~~its pipeline's success~~ and ~~the continued growth of its approved products~~. The company~~'s focus on oncology~~ and ~~autoimmune diseases positions it~~ in ~~areas of high unmet medical need~~ and ~~significant commercial potential. As Incyte advances its research and development efforts, it remains a key player in the biopharmaceutical industry~~.		Incyte is committed to corporate social responsibility and engages in various community initiatives. The company supports patient advocacy groups and participates in programs aimed at improving healthcare access and education.

			== Related pages ==
			* [[Biopharmaceutical]]
			* [[Oncology]]
			* [[Inflammation]]
			* [[Janus kinase inhibitor]]

	[[Category:Biopharmaceutical companies]]		[[Category:Biopharmaceutical companies]]
	[[Category:Companies based in Wilmington, Delaware]]		[[Category:Companies based in Wilmington, Delaware]]
	[[Category:~~Pharmaceutical companies of the United States~~]]		[[Category:Companies established in 1991]]

	~~{{pharma-stub}}~~

Prab: CSV import

2024-03-26T17:17:53Z

CSV import

New page

'''Incyte Corporation''' is an American [[biopharmaceutical]] company based in [[Wilmington, Delaware]]. Founded in 1991, Incyte has grown into a leading entity focused on the discovery, development, and commercialization of proprietary therapeutics. The company's efforts are primarily directed towards oncology, including both hematologic and solid tumor malignancies, as well as autoimmune diseases.

==History==
Incyte was established in Palo Alto, California, but later moved its headquarters to Wilmington, Delaware. Initially, the company focused on genomic and bioinformatics research, leveraging the burgeoning field of genomics to identify novel drug targets. Over the years, Incyte transitioned from genomics research to drug development, focusing on small molecule drugs and monoclonal antibodies for the treatment of cancer and autoimmune diseases.

==Products and Pipeline==
Incyte's portfolio includes a range of approved products and investigational compounds in various stages of clinical development. One of the company's most notable products is '''Jakafi''' (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor approved by the [[U.S. Food and Drug Administration]] (FDA) for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. Other products in Incyte's portfolio target different mechanisms of action and pathways involved in disease progression.

The company's research and development pipeline is robust, with multiple compounds being investigated for the treatment of various cancers and autoimmune conditions. Incyte's commitment to innovation is reflected in its ongoing clinical trials and research collaborations aimed at discovering new therapeutic options for patients.

==Collaborations==
Incyte has established several strategic collaborations with other pharmaceutical and biotechnology companies. These partnerships leverage Incyte's discovery and development capabilities and provide access to additional resources and expertise. Through these collaborations, Incyte aims to accelerate the development of its pipeline and bring new therapies to market more efficiently.

==Corporate Responsibility==
Incyte is committed to ethical business practices and corporate responsibility. The company's initiatives focus on patient access to medications, environmental sustainability, and community engagement. Incyte's patient assistance programs are designed to support patients who may not have access to their medications due to financial constraints.

==Challenges and Controversies==
Like many companies in the pharmaceutical industry, Incyte faces challenges related to drug pricing, regulatory hurdles, and competition. The company's success depends on its ability to navigate these challenges while continuing to innovate and develop new therapies.

==Future Outlook==
Incyte's future prospects are closely tied to its pipeline's success and the continued growth of its approved products. The company's focus on oncology and autoimmune diseases positions it in areas of high unmet medical need and significant commercial potential. As Incyte advances its research and development efforts, it remains a key player in the biopharmaceutical industry.

[[Category:Biopharmaceutical companies]]
[[Category:Companies based in Wilmington, Delaware]]
[[Category:Pharmaceutical companies of the United States]]

{{pharma-stub}}

Incyte - Revision history

Prab: CSV import

Prab: CSV import